Form D · Biotechnology
MICELL TECHNOLOGIES INC
Durham, NC · CIK 0001060368
Offering snapshot reported Sep 19, 2017 · SEC filing
- Reported sold
- $61.8M Offering amount: $70M
- Investors reported
- 51 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 1, 2017 As reported in this filing
Fundraising history
Reported soldDates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.
What changed?
Latest filing versus its linked predecessor, where available.
- Reported sold$41,775,000 → $61,775,000
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 19, 2017 | Amendment | $61,775,000 | $20,000,000vs Jun 21, 2017 | 51 | SEC filing |
| Jun 21, 2017 | Amendment | $41,775,000 | $10,000,000vs Apr 4, 2017 | 51 | SEC filing |
| Apr 4, 2017 | Amendment | $31,775,000 | $6,000,000vs Nov 18, 2016 | 51 | SEC filing |
| Nov 18, 2016 | Initial | $25,775,000 | No comparison | 51 | SEC filing |
| Dec 3, 2009 | Initial | $300,055 | No comparison | 12 | SEC filing |
| Jul 29, 2009 | Initial | $5,000,000 | No comparison | 9 | SEC filing |
| Aug 11, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Jun 15, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Jul 7, 2006 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Feb 24, 2005 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity, Debt, Other
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $28K
- Finders' fees
- $0
- Form D file number
- 021-274784
Offer and sale of Preferred Return Notes, and the underlying shares of Preferred Stock and Common Stock issuable upon conversion thereof.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Invemed Associates LLC | 6728 |
Source: Form D, filed Sep 19, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Arthur J. Benevenuto | Director, Executive |
| Arthur J. Benvenuto | Director, Executive |
| Archibald Cox | Director |
| Archibald Cox, Jr. | Director |
| David A. Dresner | Director |
| Daniel Estay | Director, Executive |
| Invemed Catalyst Fund, L.P. | Promoter |
| Jack Herman | Executive |
| James A. Klein | Executive |
| James A. Klein, Jr. | Executive |
| Robert S. Langer | Director |
| Kenneth G. Langone | Director |
| John Lowry | Director |
| James B Mc Clain | Executive |
| Timothy Mc Mahon | Executive |
| Stewart Noble, Ph.D. | Executive |
| General Electric Pension Trust | Promoter |
| Michael Stansky | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
801 Capitola Drive Suite 1
Durham, NC, 27713
Durham, NC, 27713